Literature DB >> 30366652

VISA-Daptomycin non-susceptible Staphylococcus aureus frequently demonstrate non-susceptibility to Telavancin.

Louis D Saravolatz1, Joan Pawlak2.   

Abstract

Telavancin was evaluated against S. aureus isolates with reduced susceptibility to other antimicrobial agents using two broth microdilution methods and Etest® strips. The three methods provided comparable results. Differences in telavancin susceptibility versus non-susceptibility were noted mainly in the VISA-daptomycin non-susceptible group of isolates. In this group the percent susceptibility was 38% for the Etest® method and 50% and 54% for the 2 broth microdilution methods. All differences in susceptibility were within one 2-fold dilution.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLSI; Daptomycin; Methicillin-resistant Staphylococcus aureus; Staphylococcus aureus; Telavancin

Mesh:

Substances:

Year:  2018        PMID: 30366652     DOI: 10.1016/j.diagmicrobio.2018.09.003

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  2 in total

1.  Evaluation of telavancin susceptibility in isolates of Staphylococcus aureus with reduced susceptibility to vancomycin.

Authors:  Allison R McMullen; William Lainhart; Meghan A Wallace; Angela Shupe; Carey-Ann D Burnham
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-08-24       Impact factor: 3.267

2.  Clinical Experience with Telavancin: Real-World Results from the Telavancin Observational Use Registry (TOUR™).

Authors:  Adam M Bressler; Ali A Hassoun; Louis D Saravolatz; Valerie Ravenna; Chris N Barnes; Bibiana Castaneda-Ruiz
Journal:  Drugs Real World Outcomes       Date:  2019-12
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.